In the first test (the Ames test), they exposed bacteria to AOD9604 to see if it caused mutations
intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 Medical Disclaimer The content in this calculator is for informational purposes only and does not constitute medical advice
A 2001 study published in the journal Obesity Research demonstrated that AOD 9604 stimulated lipolysis and inhibited lipogenesis in laboratory settings
It provides vitamin B12 and selenium for treatment and control of deficiency
The peptides primary strength lies in its selective action on fat metabolism without systemic effects on insulin, glucose, IGF-1, cortisol, or appetite-regulating pathways
AOD 9604, an innovative peptide therapy, may be the solution you've been seeking